New pill targets hard-to-treat KRAS G12D cancers in early trial
Disease control
Recruiting now
This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC